Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
eqs_en 
0 20.04.23
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
eqs_en 
0 20.04.23
Sartorius Stedim Biotech SA: First-quarter results 2023 of Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: First-quarter results 2023 of Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: First-quarter results 2023 of Sartorius Stedim Biotech
eqs_en 
0 20.04.23
EQS-News: Abivax reports 2022 financial results and operations update
EQS-News: Abivax reports 2022 financial results and operations update
EQS-News: Abivax reports 2022 financial results and operations update
eqs_en 
0 19.04.23
EQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer
EQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer
EQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer
eqs_en 
0 18.04.23
EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
eqs_en 
0 17.04.23
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
eqs_en 
0 12.04.23
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
eqs_en 
0 12.04.23
EQS-News: Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
EQS-News: Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
EQS-News: Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
eqs_en 
0 05.04.23
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
eqs_en 
0 04.04.23
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
eqs_en 
0 04.04.23
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
eqs_en 
0 04.04.23
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
eqs_en 
0 03.04.23
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech to acquire Polyplus
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech to acquire Polyplus
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech to acquire Polyplus
eqs_en 
0 31.03.23
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Lonza Launches Share Buyback Program of up to CHF 2 Billion
eqs_en 
0 31.03.23
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
eqs_en 
0 30.03.23
EQS-News: ​​​​​Eckert & Ziegler: Successful fiscal year 2022
EQS-News: ​​​​​Eckert & Ziegler: Successful fiscal year 2022
EQS-News: ​​​​​Eckert & Ziegler: Successful fiscal year 2022
eqs_en 
0 30.03.23
EQS-News: ​​​​​Eckert & Ziegler: Successful fiscal year 2022
EQS-News: ​​​​​Eckert & Ziegler: Successful fiscal year 2022
EQS-News: ​​​​​Eckert & Ziegler: Successful fiscal year 2022
eqs_en 
0 30.03.23
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
eqs_en 
0 29.03.23
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
eqs_en 
0 29.03.23
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
eqs_en 
0 28.03.23
Transgene Announces Upcoming Investor Meetings
Transgene Announces Upcoming Investor Meetings


Regulatory News:



TRANSGENE (Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that Management will participate in

BusinessWire_EN 
0 27.03.23
Sartorius Stedim Biotech SA: René Fáber takes over as Chief Executive Officer of Sartorius Stedim Biotech S.A.; Joachim Kreuzburg remains Chairman of the Board
Sartorius Stedim Biotech SA: René Fáber takes over as Chief Executive Officer of Sartorius Stedim Biotech S.A.; Joachim Kreuzburg remains Chairman of the Board
Sartorius Stedim Biotech SA: René Fáber takes over as Chief Executive Officer of Sartorius Stedim Biotech S.A.; Joachim Kreuzburg remains Chairman of the Board
eqs_en 
0 27.03.23
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
eqs_en 
0 27.03.23
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
eqs_en 
0 27.03.23